4,268 results match your criteria Journal of Thoracic Oncology[Journal]


Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis.

J Thorac Oncol 2019 Apr 15. Epub 2019 Apr 15.

Department of surgery.

Background: Up to 32% of patients with esophageal cancer show a pathological complete response (ypCR) after neoadjuvant therapy. In order to prevent overtreatment, the indication to perform esophagectomy in these patients should be reconsidered. Implementing an organ preserving strategy for patients with ypCR requires an accurate assessment of residual disease after neoadjuvant treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.04.004DOI Listing

Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.

J Thorac Oncol 2019 Apr 15. Epub 2019 Apr 15.

College of Medicine and Public Health, Flinders University, Adelaide SA 5042 Australia.

Introduction: There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required to guide treatment decisions. A lung immune prognostic index (LIPI) was recently developed to predict ICI treatment outcomes and we aim to evaluate whether LIPI is predictive of survival and response for patients treated with atezolizumab for advanced non-small cell lung cancer (NSCLC).

Methods: Pooled analysis of patient-level data of four clinical trials of atezolizumab for NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.04.006DOI Listing

Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients.

J Thorac Oncol 2019 Apr 15. Epub 2019 Apr 15.

Université Côte d'Azur, University Hospital Federation OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France;; Université Côte d'Azur, CNRS, INSERM, Institute of Research on Cancer and Ageing of Nice (IRCAN), University Hospital Federation OncoAge, Nice, France;; Université Côte d'Azur, University Hospital Federation OncoAge, Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, Nice, France;. Electronic address:

Introduction: The detection of a ROS1 rearrangement in advanced and metastatic lung adenocarcinoma (LUAD) lead to a targeted treatment with tyrosine kinase inhibitors, with favorable progression-free survival and overall survival of the patients. Thus, it is mandatory to screen for the ROS1 rearrangement in all these patients. ROS1 rearrangements can be detected using break-apart fluorescence in situ hybridization (FISH), which is the "gold standard"; however, ROS1 immunohistochemistry (IHC) can be used as a screening test since it is widely available, easy and rapid to perform, and cost-effective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.024DOI Listing

Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.

J Thorac Oncol 2019 Apr 9. Epub 2019 Apr 9.

Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:

Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been demonstrated in early phase trials in the US and East Asia. Here we present data on efficacy and safety of a prospective phase 2 trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193027
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.03.020DOI Listing
April 2019
13 Reads

The landscape of actionable molecular alterations in immunomarker-defined large cell carcinoma of lung.

J Thorac Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, the Chinese University of Hong Kong, Hong Kong; Li Ka-Shing Institute of Health Sciences, Sir Y.K. Pao Cancer Center, the Chinese University of Hong Kong, Hong Kong; Institute of Digestive Disease, State Key Laboratory of Digestive Disease, the Chinese University of Hong Kong, Hong Kong. Electronic address:

Introduction: Patients with pulmonary large cell carcinoma (LCC) have poor prognosis and limited treatment option. The identification of clinically actionable molecular alterations helps to guide personalized cancer treatment decisions.

Patients And Methods: A consecutive cohort of 789 resected non-small cell lung carcinomas (NSCLCs) were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.021DOI Listing
April 2019
1 Read

Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.

J Thorac Oncol 2019 Apr 5. Epub 2019 Apr 5.

University of California, San Francisco; San Francisco, CA USA. Electronic address:

Introduction: Despite adoption of molecular biomarkers in the management of non-small cell lung cancer (NSCLC), the recently adopted 8 Edition staging utilized only clinicopathologic characteristics, and validated improvement in risk stratification of early-stage disease remains elusive. We therefore evaluated the integration of a clinically-validated molecular prognostic classifier into conventional staging.

Methods: A novel staging system, TNMB ("B" denoting Biology), that integrates a 14-gene molecular prognostic classifier into the 8 Edition, was developed using data from 321 NSCLC patients at the University of California, San Francisco. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.015DOI Listing

Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.

J Thorac Oncol 2019 Apr 3. Epub 2019 Apr 3.

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address:

Introduction: Lung cancer incidence is higher among AAs compared with European Americans in the United States. We, and others, previously demonstrated a relationship between immune and inflammation proteins with lung cancer in European Americans. Our aim was to investigate the etiological relationship between inflammation and lung cancer in African Americans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.014DOI Listing

Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.

J Thorac Oncol 2019 Apr;14(4):e82-e84

China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.008DOI Listing

Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.

J Thorac Oncol 2019 Apr;14(4):e81-e82

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China 510080. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.015DOI Listing
April 2019
5.282 Impact Factor

A Case of Cushing Syndrome in ACTH-Secreting Thymic Paraganglioma.

J Thorac Oncol 2019 Apr;14(4):e79-e81

Department of Thoracic Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.009DOI Listing
April 2019
1 Read

Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors.

J Thorac Oncol 2019 Apr;14(4):e77-e78

Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.035DOI Listing

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.

J Thorac Oncol 2019 Apr;14(4):e75-e77

Department of Medical Oncology, Stanford Cancer Institute, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.030DOI Listing

Sequential Atezolizumab Achieved Remarkable Efficacy After Local Radiotherapy in a Patient With Lung Adenocarcinoma Refractory to Nivolumab.

J Thorac Oncol 2019 Apr;14(4):e74-e75

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.029DOI Listing

SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing.

J Thorac Oncol 2019 Apr;14(4):e72-e73

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.027DOI Listing

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.

J Thorac Oncol 2019 Apr;14(4):e70-e72

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.026DOI Listing
April 2019
1 Read

Thymic Carcinoma With Thyroid Transcription Factor-1 Expression: An Insidious Pitfall.

J Thorac Oncol 2019 Apr;14(4):e68-e70

Thoracic Surgery Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.09.030DOI Listing

Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Apr;14(4):e65-e68

Department of Radiation Oncology, Xiamen Humanity Hospital, Fujian, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.031DOI Listing
April 2019
1 Read
5.282 Impact Factor

Author's Reply to the: Letter to the Editor.

J Thorac Oncol 2019 Apr;14(4):e63-e64

The Christie NHS Foundation Trust Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.003DOI Listing

Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.

Authors:
Lubina Arjyal

J Thorac Oncol 2019 Apr;14(4):e63

Gundersen Health System, La Crosse, Wisconsin. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.033DOI Listing

Erratum.

Authors:

J Thorac Oncol 2019 Apr;14(4):744

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.018DOI Listing

Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.

Authors:
Shun Lu Ziming Li

J Thorac Oncol 2019 Apr;14(4):580-582

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.021DOI Listing

A Targeted Approach to the Complications of Targeted Therapy.

J Thorac Oncol 2019 Apr;14(4):577-579

University of Queensland Thoracic Research Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.034DOI Listing

Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?

J Thorac Oncol 2019 Apr;14(4):574-576

Department of Pulmonology, Aladar Petz University Teaching Hospital, Győr, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.004DOI Listing

Tumor heterogeneity and testing discrepancy confound ROS1 detection in NSCLC.

J Thorac Oncol 2019 Mar 23. Epub 2019 Mar 23.

Department of Medical Oncology, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA. 94305. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.011DOI Listing

Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.

J Thorac Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Surgery, Maxima Medical Center, Veldhoven, PO BOX 7777, 5500 MB Veldhoven, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.032DOI Listing
March 2019
1 Read

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.

J Thorac Oncol 2019 Mar 19. Epub 2019 Mar 19.

Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address:

Introduction: At the prior data cut-off (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (ALK+ NSCLC) (hazard ratio [HR], 0.47, 95% confidence internal [CI], 0.34-0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.007DOI Listing

BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis.

J Thorac Oncol 2019 Mar 6. Epub 2019 Mar 6.

Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.

Side effects of immune checkpoint inhibitors, termed immune-related adverse events (irAEs), are relatively common but immune checkpoint inhibitor mediated cardiotoxicity are rare, although can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report 3 patients with non-small cell lung cancer who developed pericarditis during therapy with PD-1/PD-L1 +/- CTLA-4 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.026DOI Listing
March 2019
1 Read

Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study.

J Thorac Oncol 2019 Mar 6. Epub 2019 Mar 6.

Rafal Dziadziuszko, Medical University of Gdansk, Poland.

Introduction: In an earlier report of ASCEND-8 study (open-label, phase 1, 3-arm study, treatment-naïve patients and pre-treated, advanced/metastatic NSCLC), it was shown that ceritinib 450 mg with food had comparable exposure and better gastrointestinal tolerability than 750-mg fasted.

Methods: Here, we report efficacy and updated safety data from primary efficacy analysis of ASCEND-8 study. Key secondary endpoints were overall response rate (ORR) and duration of response (DOR), assessed by blinded independent review committee (BIRC) using RECIST 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.002DOI Listing
March 2019
5.282 Impact Factor

Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

J Thorac Oncol 2019 Mar 7. Epub 2019 Mar 7.

Section of Thoracic Surgery, University of Chicago, Chicago, Illinois.

2018 was a banner year for all thoracic oncology, but especially for early-stage NSCLC. Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel "cancer personalized profiling by deep sequencing" circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received two doses of preoperative nivolumab; in September 2018, at the 19th World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.029DOI Listing
March 2019
3 Reads

Honoring the Past, Embracing the Present, You Are the Future.

J Thorac Oncol 2019 Apr 6;14(4):571-573. Epub 2019 Mar 6.

International Association for the Study of Lung Cancer. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.012DOI Listing
April 2019
2 Reads

Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers.

J Thorac Oncol 2019 Mar 1. Epub 2019 Mar 1.

Department of Pathology; Human Oncology and Pathogenesis Program. Electronic address:

Introduction: Multiple genetic mechanisms have been identified in EGFR-mutant lung cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI) but many cases still lack a known mechanism.

Methods: To identify novel mechanisms of AR, we performed targeted large panel sequencing on 374 consecutive patients with metastatic EGFR-mutant lung cancer, including 174 post-TKI samples of which 38 patients also had a matched pre-TKI sample. Alterations hypothesized to confer AR were introduced into drug-sensitive EGFR-mutant lung cancer cell lines (H1975, HCC827, PC9) using CRISPR-Cas9 genome editing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.038DOI Listing
March 2019
1 Read

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

J Thorac Oncol 2019 Feb 27. Epub 2019 Feb 27.

Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland. Electronic address:

Introduction: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported in several retrospective trials or small series in advanced pretreated NSCLC with HER2 mutations. We report the first prospective evaluation of afatinib for the treatment of this molecularly defined entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.017DOI Listing
February 2019
1 Read

The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 27. Epub 2019 Feb 27.

Division of Medical Oncology, Department of Internal Medicine, James Thoracic Center, The Ohio State University, Columbus, Ohio. Electronic address:

Introduction: Liver kinase B1 (LKB1), also called serine/threonine kinase 11 (STK11), is a tumor suppressor that functions as master regulator of cell growth, metabolism, survival, and polarity. Approximately 30% to 35% of patients with NSCLC possess inactivated liver kinase B1 gene (LKB1), and these patients respond poorly to anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy. Therefore, novel therapies targeting NSCLC with LKB1 loss are needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.019DOI Listing
February 2019

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.

J Thorac Oncol 2019 Feb 26. Epub 2019 Feb 26.

Pfizer Oncology, La Jolla, California.

Introduction: We retrospectively analyzed the effects of crizotinib on serum creatinine and creatinine-based estimated glomerular filtration rate (eGFR) in patients with anaplastic lymphoma kinase-positive advanced NSCLC across four trials (NCT00585195, NCT00932451, NCT00932893, and NCT01154140).

Methods: Changes from baseline data in serum creatinine and eGFR, calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine-based equation, were assessed over time. eGFR was graded using standard chronic kidney disease criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.015DOI Listing
February 2019
2 Reads

The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

J Thorac Oncol 2019 Mar;14(3):e60-e61

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.018DOI Listing

PCI in Small Cell-Review the Cohorts.

J Thorac Oncol 2019 Mar;14(3):e59-e60

Department of Radiation Oncology and Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.007DOI Listing

Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.

J Thorac Oncol 2019 Mar;14(3):e55-e57

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.025DOI Listing
March 2019
2 Reads

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

J Thorac Oncol 2019 Mar;14(3):e50-e52

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.012DOI Listing
March 2019
5.282 Impact Factor

Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.

J Thorac Oncol 2019 Mar;14(3):e49-e50

Department of Pneumology, AZ Sint-Blasius Hospital, Dendermonde, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.014DOI Listing
March 2019
1 Read

Erratum.

Authors:

J Thorac Oncol 2019 Mar;14(3):560

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.001DOI Listing
March 2019
1 Read

Lung Cancer Screening in Never-Smokers.

Authors:
Stephen Lam

J Thorac Oncol 2019 Mar;14(3):336-337

British Columbia Cancer and the University of British Columbia, Vancouver, British Columbia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.019DOI Listing
March 2019
1 Read

Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

J Thorac Oncol 2019 Mar;14(3):332-335

Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.017DOI Listing

Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

J Thorac Oncol 2019 Mar;14(3):328-331

Medical School, Paris-Saclay University, Paris-Sud University, Le Kremlin Bicêtre, France; Drug Development Department (DITEP), Gustave Roussy Institute, Paris Saclay University, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.011DOI Listing

Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?

J Thorac Oncol 2019 Mar;14(3):326-327

Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Centre, GROW School of Oncology and Developmental Biology, Maastricht, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.016DOI Listing
March 2019
1 Read

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Paris-Sud University, Orsay, France.

Introduction: Although frequent in NSCLC, patients with brain metastases (BMs) are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less-selected NSCLC cohort.

Methods: Data from consecutive patients with advanced ICI-treated NSCLC were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.009DOI Listing
February 2019
1 Read

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address:

Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.008DOI Listing
February 2019
3 Reads

Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.

J Thorac Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of radiation oncology, Jean Bernard center, Inter-regional Institute of Oncology, Le Mans, France.

Background: A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance following initial treatment for lung cancer compared with conventional surveillance. The aim of this study was to assess the cost-effectiveness of this PRO-based surveillance in lung cancer patients.

Methods: This medico-economic analysis employed data from the clinical trial, augmented by abstracted chart data and costs of consultations, imaging, transportations, information technology, and treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.005DOI Listing
February 2019
1 Read